logo

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Medivation Technologies, Inc.


USPTO Granted Patents = 63



Forward Citations = 720

Loading Chart...
Loading Chart...

40 inventors (with patents filed for the assignee):

goldMedal Sarvajit Chakravarty (54 out of 87 patents)

silverMedal Rajendra Parasmal Jain (45 out of 48 patents)

bronzeMedal Andrew Asher Protter (26 out of 35 patents)

4.  David T Hung (19 out of 42 patents)

5.  Roopa Rai (8 out of 21 patents)

6.  Sundeep Dugar (8 out of 80 patents)

7.  Bing Wang (7 out of 64 patents)

8.  Barry Patrick Hart (7 out of 10 patents)

9.  Michael J Green (7 out of 60 patents)

10.  Daniel T Chu (7 out of 98 patents)

11.  Son Minh Pham (6 out of 25 patents)

12.  Brahmam Pujala (6 out of 21 patents)

13.  Bharat Uttam Shinde (5 out of 5 patents)

14.  Anjan Kumar Nayak (4 out of 11 patents)

15.  Sreekanth A Ramachandran (4 out of 8 patents)


Core Competencies:
Dihydropyridophthalazinone
Poly(ADP-ribose)polymerase
Heterocyclic Compounds
Pyrido[3,4-b] Indoles
Fused Pyrimidine Compounds
Azepino[4,5-B] Indoles
Tetracyclic Compounds
Bridged Heterocyclic Compounds
Substituted Phenylcarbamoyl Compounds
Diabetes Treatment
Hypertension Treatment
PTEN Deficiency

63 patents:

1. 11702401 - Compounds and methods of use (2023-07-18),
2. 11364241 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) (2022-06-21),
3. 11053216 - Compounds and methods of use (2021-07-06),
4. 10780088 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) (2020-09-22),
5. 10543209 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) (2020-01-28),
6. 10501436 - Compounds and methods of use (2019-12-10),
7. 10493078 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency (2019-12-03),
8. 10189837 - Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt (2019-01-29),
9. 10189826 - Heterocyclic compounds and methods of use (2019-01-29),
10. 10183015 - Heterocyclic compounds and methods of use (2019-01-22),
11. 10030004 - Compounds and methods of use (2018-07-24),
12. 9926303 - Processes of synthesizing dihydropyridophthalazinone derivatives (2018-03-27),
13. 9820985 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) (2017-11-21),
14. 9670172 - Heterocyclic compounds and methods of use (2017-06-06),
15. 9580425 - Pyrido[3,4-b] indoles and methods of use (2017-02-28),
Medivation Technologies, Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of serious diseases. The company specializes in oncology and aims to provide novel solutions to improve the lives of patients worldwide. With a strong commitment to scientific excellence, Medivation Technologies collaborates with leading researchers and partners to advance the discovery and development of cutting-edge treatments. To learn more about their pioneering work, please visit their website.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

...
63 Patents

#81 in San Francisco, CA

#1,305 in California

#5,530 in US

#11,193 in the World

...
San Francisco, CA, United States of America

Medivation Technologies, Inc.

Forward Citations = 720

40 inventors:

goldMedal Sarvajit Chakravarty (54 out of 87 patents)

silverMedal Rajendra Parasmal Jain (45 out of 48 patents)

bronzeMedal Andrew Asher Protter (26 out of 35 patents)

4.  David T Hung (19 out of 42 patents)

5.  Roopa Rai (8 out of 21 patents)

Please report any incorrect information to support@idiyas.com
Loading…